» Articles » PMID: 16407690

Pharmacotherapy Review: Calcium Channel Blockers

Overview
Date 2006 Jan 13
PMID 16407690
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

As a drug class, calcium channel blockers encompass a heterogeneous group of compounds with distinctive structures and pharmacologic characteristics. These agents are widely used in the treatment of hypertension, chronic coronary ischemia, and/or supraventricular arrhythmias. Much of the early debate alluding to increased cardiovascular risk associated with calcium channel blocker use has been silenced by an array of outcomes trials that show these drugs to be both safe and effective in reducing hard cardiovascular end points. The most common side effects associated with calcium channel blockers are vasodilatory in nature and include a non-volume-dependent form of peripheral edema, flushing, and headache. Despite the sometimes discomforting side effects seen with calcium channel blocker therapy, their robust blood pressure-lowering effect makes them an important component of most multidrug regimens used for blood pressure control.

Citing Articles

The Evolving Role of Calcium Channel Blockers in Hypertension Management: Pharmacological and Clinical Considerations.

Jones K, Hayden S, Meyer H, Sandoz J, Arata W, Dufrene K Curr Issues Mol Biol. 2024; 46(7):6315-6327.

PMID: 39057019 PMC: 11275245. DOI: 10.3390/cimb46070377.


Tolerability of Antihypertensive Medications: The Influence of Age.

Rivasi G, Coscarelli A, Capacci M, Ceolin L, Turrin G, Tortu V High Blood Press Cardiovasc Prev. 2024; 31(3):261-269.

PMID: 38658522 PMC: 11161422. DOI: 10.1007/s40292-024-00639-z.


Single-pill fixed-dose drug combinations to reduce blood pressure: the right pill for the right patient.

Sarzani R, Laureti G, Gezzi A, Spannella F, Giulietti F Ther Adv Chronic Dis. 2022; 13:20406223221102754.

PMID: 35769133 PMC: 9235298. DOI: 10.1177/20406223221102754.


Anticancer Effects of Amlodipine Alone or in Combination With Gefitinib in Non-Small Cell Lung Cancer.

Fu B, Dou X, Zou M, Lu H, Wang K, Liu Q Front Pharmacol. 2022; 13:902305.

PMID: 35721193 PMC: 9198715. DOI: 10.3389/fphar.2022.902305.


Integrated Serum Pharmacochemistry and Network Pharmacology Approach to Explore the Effective Components and Potential Mechanisms of Menispermi Rhizoma Against Myocardial Ischemia.

Wei J, Yu Y, Zhang Y, Li L, Li X, Shao J Front Chem. 2022; 10:869972.

PMID: 35665070 PMC: 9160829. DOI: 10.3389/fchem.2022.869972.


References
1.
Staessen J, Wang J, Thijs L . Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet. 2001; 358(9290):1305-15. DOI: 10.1016/S0140-6736(01)06411-X. View

2.
Turnbull F . Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003; 362(9395):1527-35. DOI: 10.1016/s0140-6736(03)14739-3. View

3.
Chobanian A, Bakris G, Black H, Cushman W, Green L, Izzo Jr J . Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42(6):1206-52. DOI: 10.1161/01.HYP.0000107251.49515.c2. View

4.
Turnbull F, Neal B, Algert C, Chalmers J, Chapman N, Cutler J . Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005; 165(12):1410-9. DOI: 10.1001/archinte.165.12.1410. View